Skip to main content
Equibles
PBH logo

PBH · Prestige Consumer Healthcare Inc.

Track PBH — free

Use PBH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PBH

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$51.38 +0.06 (+0.12%) At close · Aug 14
Market Cap
$2.43B
Shares
47.37M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$51.38 Open$51.07 Day$50.36–52.00 52W close$45.44–70.21 Avg vol 30d536K Short int3.8M · 8.1% float · 8.1d Short vol65% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 12 wks
FQ2-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −11%
      below
      Price vs 50-day avg +4%
      above
      RSI (14) 51
      neutral
      MACD trend Negative
      52-week position 24%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +3%
      trailing
      6-month return −26%
      trailing
      YTD return −17%
      this year
      Relative strength −40%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $49 › 200d $57 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +42 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      8.06% of float · ▲ +23.7% MoM · 8.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      315 holders — mid 3-yr range
      Squeeze score 77
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +37%
      Y/Y
      Gross margin 61%
      contracting
      EPS growth −9%
      Y/Y
      Free cash flow $246.4M
      Valuation P/E 14.4
      below peers
      Buyback $92.2M
      remaining
      Balance sheet $930.1M
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 31%
      annualized · 1-yr
      Max drawdown −35%
      past year
      ATR 3.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 5
      Latest guidance · from the 8-K filed Aug 6, 2026
      Revenue · fiscal 2027 $1.29B – $1.32B
      Adjusted Diluted EPS · fiscal 2027 Non-GAAP $4.55 – $4.65
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2024
      Gross margin · full fiscal year 56%
      Gross margin · Q3 55%
      A&M as a percent of sales · Q3 13%
      Tax rate · remaining quarters of fiscal '25 24%
      G&A as a percent of sales · full fiscal year 9.5%
      Free cash flow · full year at least $240M
      Guided vs delivered · last 5 settled
      Revenue Fiscal 2026
      guided $1.1B – $1.12B
      $1.09B Miss −1.7%
      Revenues Q1
      guided $260M
      $267.14M Beat +2.7%
      Revenue fiscal '25
      guided $1.13B – $1.14B
      $1.14B In line
      EPS fiscal '25
      guided $4.40 – $4.46
      $4.29 Miss −3.2%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −11% Bearish
      Price vs 50-day avg
      +4% Bullish
      RSI (14)
      51 Neutral
      MACD trend
      Negative Bearish
      52-week position
      24% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $49 › 200d $57 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +42 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      8.06% of float · ▲ +23.7% MoM · 8.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      315 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $45 Now $51 · 24% Range high $70
      vs 200-day avg -11% vs 50-day avg +4%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted Non-GAAP Free Cash Flow non-GAAP $83.7M Q1 FY2027 —
      Non-GAAP Adjusted Diluted EPS non-GAAP $0.98 Three Months Ended June 30, 2026 —
      Non-GAAP Adjusted EBITDA non-GAAP 84.05M Three Months Ended June 30, 2026 —
      Non-GAAP Adjusted EBITDA Margin non-GAAP 31.6% Three Months Ended June 30, 2026 —
      Non-GAAP Adjusted Gross Margin non-GAAP 146.18M Three Months Ended June 30, 2026 —
      Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues non-GAAP 55% Three Months Ended June 30, 2026 —
      Non-GAAP Adjusted Net Income non-GAAP 46.5M Three Months Ended June 30, 2026 —
      Non-GAAP Free Cash Flow non-GAAP 67.09M Three Months Ended June 30, 2026 —
      Free cash flow non-GAAP $246.4M fiscal year 2026 —
      Covenant-defined leverage ratio 2.6 as of December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PBH
      Prestige Consumer Healthcare Inc.
      this stock
      		$2.43B -16.7% -4.3% 14.4 8.1%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $56.30B +13.1% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $49.49B +2.4% — — 0.0%
      TEVA
      Teva Pharmaceutical Industries Ltd
      		 $42.85B +17.8% +4.3% 60.3 2.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      315
      % held
      112.9%
      Net QoQ
      +1.5M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      373
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      3.8M
      Days to cover
      8.1d
      Change
      +732.1K sh
      View
      Short Volume
      Short vol %
      65%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      6
      Value
      $284
      As of
      Jul 1, 2026
      View
      Off-Exchange
      Off-exchange %
      41.9%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $1.1B
      Net income (FY)
      $190.3M
      EPS diluted
      $3.91
      View
      Buybacks
      Authorized
      $300.0M
      Remaining
      $92.2M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 14, 2026
      This year
      15
      View
      Proposed Sales
      Value
      $18.4K
      Shares
      351
      Filed
      May 11, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PBH -6.3% +2.9% -26.3% +2.3% -16.7%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -6.7% -1.5% -40.0% -1.6% -30.6%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $300.00M
      Spent (derived)
      $207.80M
      Remaining
      $92.20M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1295947 CUSIP 74112D101 13F (30d) 293 filings 293 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)